‘Leukapheresis’ is a procedure used for ‘separating white blood cells from a sample of blood.’ It can be conducted to reduce the count of very high white blood cell, to obtain cells for various research purposes and to obtain autologous blood cells for further transplant back into patient. It is a type of apheresis, used for separating out a particular constituent of blood and to return the remaining part back to the circulation. The global leukapheresis market is calculated to grow from its initial estimated value of USD 19.9 million in 2018 to an estimated value of USD 34.40 million by 2026. The market is expected to record a CAGR of 7.34 per cent in the forecast period of 2019-2026. This rise in the global leukapheresis market can be ascribed to the rising number of blood donations and rising demand for leukopaks.

Global Leukapheresis Market

Some of the reasons for the growth of the global leukapheresis market include:

  • Growing prevalence of leukemia- Across the globe, the incidence of leukemia has mounted significantly. According to the National Cancer Institute (NIH) in 2015, about 405,815 people were suffering from leukemia in the United States. According to the NIH estimates, the number of new cases of leukemia has augmented on an average rate of 0.3 per cent each year over the last 10 years (from 2006 to 2015). The NIH also estimates that the number of new cases may reach 60,300 in 2018. According to the Leukemia & Lymphoma Society, from 2010 to 2014, leukemia was the sixth-most-common cause of cancer deaths globally
  • Increased Number of Blood Donations- The global demand for blood and blood components is on the increase. In the U.S. alone, approximately 44,000 units of blood are required every day in hospitals and emergency treatment facilities. About 21 million units of blood components are transfused per year in the U.S. The requirement of leukocytes/WBCs is attributed to the increase in demand for leukopaks in clinical research and the growing number of clinical trials for the development of CAR-T therapy for leukemia.

On the basis of type of leukapheresis products, the leukapheresis disposables segment accounted for the largest share of the global leukapheresis market in 2018. The large share of this segment can be ascribed to the repeated consumption of disposables in leukapheresis procedures. Due to the increasing applications of leukapheresis procedures for the isolation of primary cells from blood for cell therapy research applications, the growth of this market segment is taking place during the forecast period.

With respect to applications, the research application segment is computed to account for the largest share of the global leukapheresis market in 2018. The dominant share of this sub-segment can be assigned to the growing adoption of leukapheresis products in research activities propelled by increasing research activities being undertaken for cancer, immunology, infectious diseases, drug discovery, regenerative medicine, and cell-based therapies.

With respect to end user, the blood component providers & blood centers segment is accounted for the dominant share of the global leukapheresis market in 2018. Growth in this market is extensively driven by the increasing number of blood donations, growing demand for leukopaks for the development of CAR-T therapy, and increasing demand for leukopaks in clinical conditions like cancer.

Some of the major players in the global leukapheresis market include: Haemonetics (US), Terumo BCT (US), Asahi Kasei Medical (Japan), Fresenius (Germany), STEMCELL Technologies (Canada), and Macopharma (France). Some prominent players in the leukopaks market include: StemExpress (US), Key Biologics (US), Caltag Medsystem (UK), PPA Research Group (US), HemaCare (US), AllCells (US), ZenBio (US), Precision for Medicine (US), and BioIVT (US).

Check the report description at: Global Leukapheresis Market – Forecasts to 2026